Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors

[1]  S. Ganesan,et al.  BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. , 2018, JCO precision oncology.

[2]  A. Drilon,et al.  Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes , 2018, Nature Reviews Clinical Oncology.

[3]  Funda Meric-Bernstam,et al.  Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.

[4]  A. Iafrate,et al.  Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Yih-Leong Chang,et al.  Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. , 2017, The Lancet. Respiratory medicine.

[6]  S. Ou,et al.  Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature , 2017, Lung Cancer.

[7]  C. Paweletz,et al.  OA 09.02 Osimertinib Resistance Mediated by Loss of EGFR T790M Is Associated with Early Resistance and Competing Resistance Mechanisms , 2017 .

[8]  J. Gray,et al.  MA 12.05 Genomic Profiling of EGFR T790M Mutated Non-Small Cell Lung Cancer to Evaluate the Mechanisms of Resistance to Osimertinib , 2017 .

[9]  E. De Carlo,et al.  Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third-Generation EGFR Tyrosine Kinase Inhibitor. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  M. Erlander,et al.  Urine test for EGFR analysis in patients with non-small cell lung cancer. , 2017, Journal of thoracic disease.

[11]  S. Digumarthy,et al.  Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  S. Ou,et al.  Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients , 2017, Lung cancer.

[13]  B. Taylor,et al.  A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. , 2017, Cancer discovery.

[14]  A. Drilon,et al.  Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance , 2017, Nature Reviews Clinical Oncology.

[15]  A. Resnick,et al.  CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles , 2017, Oncogene.

[16]  V. Miller,et al.  Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  M. Varella‐Garcia,et al.  Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung Cancer. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  S. Qin,et al.  Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  P. Stephens,et al.  Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. , 2017, Lung cancer.

[20]  E. White,et al.  BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma , 2017, Clinical Cancer Research.

[21]  Lauren L. Ritterhouse,et al.  ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[23]  A. Drilon,et al.  Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). , 2017, Cancer discovery.

[24]  M. Ni,et al.  FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling , 2016, Oncogene.

[25]  Lauren L. Ritterhouse,et al.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer , 2016 .

[26]  T. Clark,et al.  Analytic validation of a clinical circulating tumor DNA assay for patients with solid tumors , 2016 .

[27]  S. Ou,et al.  High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression. , 2016, Lung cancer.

[28]  T. Taxter,et al.  FGFR3-TACC3 fusion in solid tumors: mini review , 2016, Oncotarget.

[29]  W. Liang,et al.  Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report , 2016, BMC Cancer.

[30]  Kai Wang,et al.  The distribution of BRAF gene fusions in solid tumors and response to targeted therapy , 2015, International journal of cancer.

[31]  D. Lin,et al.  Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  L. Borsu,et al.  Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. , 2015, JAMA oncology.

[33]  P. Stephens,et al.  Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. , 2015, Lung cancer.

[34]  Aleksandra Markovets,et al.  Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.

[35]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[36]  M. Ladanyi,et al.  ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[37]  William Pao,et al.  Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.

[38]  A. Iafrate,et al.  Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers , 2012, Science Translational Medicine.

[39]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[40]  S. Citi,et al.  PLEKHA7 Is an Adherens Junction Protein with a Tissue Distribution and Subcellular Localization Distinct from ZO-1 and E-Cadherin , 2010, PloS one.

[41]  R. Barrio,et al.  Regulation and function of Spalt proteins during animal development. , 2009, The International journal of developmental biology.